Skip to main content

Table 1 Correlation between nuclear CARM1 expression and the clinicopathologic characteristics of breast cancer patients

From: Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes

Clinicopathologic characteristics n Nuclear CARM1 expression P *
Negative or low expression (IHC score < 80) High or over expression (IHC score f ≥ 80)
Age(y)     
≤40 53 16 (30.2) 37 (69.8) 0.002
>40 194 105 (54.1) 89 (45.9)  
Tumor size     
≤2 cm 125 65 (52.0) 60 (48.0) 0.338
>2 cm 122 56 (45.9) 66 (54.1)  
Tumor number     
1 234 121 (51.7) 113 (48.3) <0.001
≥2 13 0 (0) 13 (100.0)  
Grade     
I&II 181 96 (53.0) 85 (47.0) 0.035
III 66 25 (37.9) 41 (62.1)  
Lymph node metastasis     
N0 127 56 (44.1) 71 (55.9) 0.113
N1, N2,N3 120 65 (54.2) 55 (45.8)  
TNM stage     
I 74 36 (48.6) 38 (51.4) 0.886
II 111 53 (47.7) 58 (52.3)  
III 62 32 (51.6) 30 (48.4)  
ER     
negative 90 35 (38.9) 55 (61.1) 0.016
positive 157 86 (54.8) 71 (45.2)  
PR     
negative 136 56 (41.2) 80 (58.8) 0.007
positive 111 65 (58.6) 46 (41.4)  
HER2     
negative 206 107 (51.9) 99 (48.1) 0.037
positive 41 14 (34.1) 27 (65.9)  
Expression of Ki67     
low (≤10%) 55 35 (63.6) 20 (36.4) 0.014
high (>10%) 192 86 (44.8) 106 (55.2)  
Expression of P53     
low 95 57 (60.0) 38 (40.0) 0.006
high 152 64 (42.1) 88 (57.9)  
  1. * P value is the result of x2 test in the same factor, and < 0.05 is considered statistically significant.